Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis | 2030
Market Size & Trends
The global acute myeloid leukemia treatment market is poised for significant expansion, with an estimated value of USD 3.47 billion by 2024. A robust growth rate of 10.6% from 2025 to 2030 is anticipated, driven primarily by the rising prevalence of acute myeloid leukemia and the growing demand for innovative treatments. Genetic mutations, unhealthy lifestyles, exposure to hazardous chemicals such as benzene, and radiation exposure are contributing factors to the increasing incidence of acute myeloid leukemia. As a result, there is a pressing need for advanced therapeutic options that can effectively manage this complex disease. Furthermore, the aging population is also contributing to the surge in healthcare needs, presenting opportunities for growth in the treatment market. As the global health landscape continues to evolve, it is likely that the acute myeloid leukemia treatment market will continue to experience significant growth, driven by innovation and a pressing need for effective treatments.
Recent advancements in targeted therapies have significantly shifted the landscape of Acute Myeloid Leukemia (AML) treatment. Building on this progress, innovative treatments such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors have emerged, offering personalized treatment plans tailored to specific genetic mutations. This tailored approach has yielded improved patient outcomes. For example, in July 2023, the FDA cleared quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the US, expanding treatment options alongside standard chemotherapy regimens.
Research efforts are underway to explore novel combinations of therapies that have shown potential in extending survival rates for patients with Acute Myeloid Leukemia (AML). Specifically, the pairing of venetoclax with azacitidine or other hypomethylating agents has garnered significant interest. Further investigation is being conducted to integrate venetoclax into established 7+3 chemotherapy regimens, a move aimed at maximizing treatment efficacy. This innovative approach underscores a growing dedication to developing comprehensive treatment strategies that hold promise for improving patient outcomes.
In addition to these groundbreaking developments, the exploration of immunotherapies, including CAR-T cell therapies, is revolutionizing AML treatment by augmenting the immune system's natural response to cancer cells. This innovative approach offers patients a glimmer of hope where conventional options may have been exhausted. Furthermore, significant strides in deciphering the genetic mutations driving AML have led to tailored treatment strategies, such as menin inhibitors specifically targeting KMT2A and NPM1 mutations.
The rising tide of Acute Myeloid Leukemia (AML) calls for innovative solutions. Driven by genetic mutations, unhealthy lifestyles, and environmental factors, this disease is taking a significant toll on individuals worldwide. As per the American Cancer Society, approximately 22,010 people are expected to be diagnosed with AML in 2025, underscoring the need for effective treatment options. Recent developments in Canada highlight the urgency of addressing this challenge. Scientists at the University of Montreal have secured a substantial USD 6 million grant from Genome Canada to develop a novel Cyclin K degrader, specifically designed for high-risk AML patients. This initiative aims to enhance treatment outcomes and drive economic growth in Canada. The development of innovative therapies for high-risk patients, coupled with significant global investments in research and development, is poised to propel market growth. Furthermore, collaborations between pharmaceutical companies and research institutions are accelerating the pace of new AML treatment development, bringing hope to those affected by this devastating disease.
Get A Free Sample Research Report PDF:
Disease Insights
The myeloblastic leukemia segment dominates the market with a substantial 43.0% share, driven by the high incidence and prevalence of this disease type, which fuels significant demand for effective treatments. The robust size of this market segment is also supported by ongoing advancements in therapy development and treatment improvements. Notably, in October 2024, the National Institute of Health launched a precision medicine clinical trial in the U.S., evaluating targeted treatment combinations for acute myeloid leukemia and myelodysplastic syndromes based on patients' genetic profiles. This initiative underscores the importance of personalized medicine approaches. Furthermore, Auron Therapeutics has secured significant funding to advance its research efforts, as announced in February 2025, when the FDA granted Fast Track designation to AUTX-703 for relapsed or refractory acute myelogenous leukemia, highlighting the urgent need for innovative treatments for patients facing poor outcomes in the U.S.
Promyelocytic leukemia is poised for significant growth over the forecast period, driven by advancements in targeted therapies and a deeper understanding of the disease's molecular underpinnings. This has led to the emergence of more effective, tailored treatment approaches that are revolutionizing patient care. Innovations such as arsenic trioxide and all-trans retinoic acid (ATRA) have transformed the treatment landscape, significantly improving survival rates while minimizing long-term side effects associated with traditional chemotherapy regimens. Ongoing research into molecular and genetic therapies is further accelerating the development and adoption of novel treatments in this market segment.
Treatment Insights
The chemotherapy segment dominates the market, accounting for 48.0% of the total share by 2024. This therapeutic approach remains a cornerstone in treating acute myeloid leukemia (AML), given its versatility across various subtypes and established success rate in achieving remission, particularly during induction therapy. A recent example of this is the 66th American Society of Hematology Annual Meeting, where three studies shed new light on AML treatment by providing insights into CPX-351 efficacy, oral maintenance therapy outcomes, and long-term data on midostaurin for high-risk patients. Furthermore, the strategic combination of chemotherapy with newer agents like low-dose cytarabine and glasdegib has enhanced outcomes for older patients and those with significant comorbidities, cementing chemotherapy's position in AML treatment strategies and ensuring its substantial market share.
The immunotherapy segment is poised to experience the fastest growth at a CAGR of 12.8% over the forecast period, driven by significant breakthroughs in targeted therapies and monoclonal antibodies that bolster the immune system's ability to combat leukemia cells. This rapid expansion has been fueled by clinical successes and expedited FDA approvals of treatments specifically targeting pathways vital for cancer cell survival. For example, new research published in July 2024 by Therapeutic Advances in Hematology sheds light on advancements in CAR therapy for AML in China, focusing on identifying specific surface markers to amplify treatment effectiveness. The prospect of immunotherapy offering durable remissions with reduced side effects compared to conventional chemotherapy, combined with ongoing clinical trials combining it with other therapies, solidifies its growing significance in AML treatment strategies. Moreover, substantial investments in research from major pharmaceutical companies further underscore the anticipated accelerated growth of this segment.
Route of Administration Insights
The parenteral route segment has maintained its market leadership with a substantial revenue share of 66.0% in 2024, largely attributed to the widespread use of intravenous administration for chemotherapy treatments such as cytarabine and anthracycline-based drugs. This method facilitates swift absorption into the bloodstream, facilitating precise dosing that effectively targets cancer cells while ensuring timely intervention during AML's critical initial treatment phases. The FDA’s recent approval of new drug combinations in 2023 further underscored the significance of this segment in effective AML management, underscoring its critical role in patient outcomes.
The oral segment is poised to witness the most substantial growth rate of 12.7% over the forecast period. The introduction of innovative oral medications such as IDH inhibitors (e.g., ivosidenib) and BCL-2 inhibitors (e.g., venetoclax) has revolutionized AML treatment, providing a more accessible alternative to traditional intravenous therapies. This breakthrough is exemplified by recent findings from the ASH Annual Meeting in December 2024, which revealed remarkable remission rates among patients with relapsed/refractory acute myeloid leukemia treated with revumenib-based combination therapy. By leveraging oral therapies, clinicians can now effectively target specific AML subtypes, ultimately shifting the paradigm towards less invasive treatments that prioritize patient comfort, reduce hospital stays, lower costs, and enhance overall satisfaction.
End Use Insights
The hospitals and clinics segment dominated the market share of 52.5% in 2024, driven by the intricate nature of Acute Myeloid Leukemia (AML) that necessitates specialized equipment, skilled healthcare professionals, and state-of-the-art facilities for optimal patient care. These medical institutions are well-equipped to deliver comprehensive treatment options, including high-dose chemotherapy and stem cell transplants, which frequently form integral components of AML treatment protocols.
The hospital infrastructure is designed to facilitate collaboration among healthcare professionals from diverse disciplines, including hematologists, oncologists, nurses, and support staff, thereby promoting a comprehensive treatment plan. In 2023, the increased focus on hospitals for AML management was underscored by the introduction of more advanced therapies requiring precise administration and monitoring, underscoring their essential role in providing specialized care.
As the demand for innovative care solutions continues to rise, the homecare setting is poised for significant growth over the forecast period. With an anticipated CAGR of 13.5%, this sector is expected to experience explosive expansion. The key driver behind this surge in growth is the increased accessibility of oral chemotherapeutics and targeted therapies, which can be administered safely at home. The rise of telehealth and remote monitoring technologies has further accelerated this trend, enabling healthcare providers to offer unwavering support and management for AML patients from the comfort of their own homes. This shift towards home care presents a vast opportunity for individuals seeking personalized attention and more flexible treatment options.
As we move forward into 2024, the growth of homecare services is being driven by healthcare policies focused on minimizing hospital readmissions and alleviating pressure on medical facilities. These initiatives also aim to enhance patient quality of life by providing accessible care within their own homes. Furthermore, the expansion of this sector is bolstered by innovative patient education programs and comprehensive home health services, guaranteeing that patients receive safe and effective treatment in a setting tailored to their unique needs.
Regional Insights
The North America acute myeloid leukemia (AML) treatment market is poised for significant expansion, driven by the adoption of innovative therapies and increasing emphasis on precision medicine. As of 2024, targeted therapies and immunotherapies have emerged as game-changers in AML treatment, demonstrating promising results in clinical trials and offering new hope for patients. The growing importance of tailored treatments has led to the development of cutting-edge solutions such as BiTE antibodies and CAR-T cell therapy, particularly for refractory cases. However, a 2024 study by the Alliance for Leukemias in Mexico highlights the need for improved access to leukemia care. The survey revealed notable disparities in care accessibility, with only 29.5% of physicians reporting the presence of a dedicated leukemia clinic and 64.2% citing diagnostic tests as a major treatment barrier. Initiatives such as the PRONAII Childhood Leukemia Project have begun to address these disparities, enhancing diagnostic capabilities, fostering collaboration, standardizing processes, and targeting states in Oaxaca, Puebla, and Tlaxcala. By reducing early mortality rates among children with leukemia, this project has made a meaningful contribution to market growth. As recent efforts continue to improve leukemia care in Mexico, the North America A
U.S. Acute Myeloid Leukemia Treatment Market Trends
In the United States, the North America acute myeloid leukemia treatment market leads the pack, boasting an impressive 90.9% share of revenue in 2024. The country's unique blend of stringent regulatory requirements and high healthcare spending plays a significant role in shaping the market's dynamics. The FDA, as the primary gatekeeper for new therapies, assumes a critical role in evaluating efficacy and safety standards before approving treatments. This rigorous process ensures that only the most promising candidates make it to market, ultimately safeguarding patients' well-being. Moreover, the high cost of healthcare in the U.S. allows patients access to cutting-edge treatments, fueling the rapid adoption of novel therapies. For example, ImCheck Therapeutics secured FDA Fast Track designation in September 2024 for ICT01, a groundbreaking treatment combining azacitidine and venetoclax, specifically designed for AML patients who cannot tolerate intensive chemotherapy.
Europe Acute Myeloid Leukemia Treatment Market Trends
The Europe acute myeloid leukemia (AML) treatment market is marked by a nuanced interplay of regulatory frameworks and regional cultural nuances. A notable trend shaping the market is the growing emphasis on cost-effectiveness and value-based healthcare systems across European countries. These approaches enable health technology assessment agencies to rigorously evaluate new therapies, prioritizing clinical benefits and economic impact in determining market access for AML treatments.
The German acute myeloid leukemia treatment market has seen notable advancements in recent years, with a clinical trial pushing the boundaries of traditional stem cell transplantation methods. For example, researchers at the German Cancer Research Center (DKFZ), Heidelberg University Hospital, and HI-STEM recently made a significant breakthrough in identifying a marker for therapy response in acute myeloid leukemia. This discovery enables the development of a cost-effective test that can predict the efficacy of the Venetoclax and 5-Azacitidine combination treatment, thereby optimizing transplantation approaches. Furthermore, the 2025 EHA-SWG Scientific Meeting in Berlin provided a platform to discuss recent advances in secondary AML, reflecting the rising incidence and improved diagnostics that are driving demand for innovative therapies in Germany.
Asia Pacific Acute Myeloid Leukemia Treatment Market Trends
The Asia Pacific market for acute myeloid leukemia (AML) treatment is poised for substantial growth, driven by a unique blend of economic, regulatory, and cultural factors. With an anticipated CAGR of 11.7%, the region is set to witness a significant transformation in AML treatment strategies. In countries like China and Japan, the rising incidence of AML, combined with improved healthcare infrastructure, has created a strong demand for innovative therapies. As a result, regulatory bodies in the Asia Pacific are actively working towards simplifying approval processes for new treatments, thereby expediting patient access to cutting-edge care. This strategic shift is likely to have a profound impact on the region's AML treatment landscape, ultimately benefiting patients and healthcare providers alike.
The acute myeloid leukemia (AML) treatment market in Japan is poised for significant growth, with a predicted rate of 12.9% over the forecast period. As the country's aging population continues to rise, older adults are increasingly affected by AML. Recent breakthroughs in diagnostic technology have also enabled earlier detection and intervention. Furthermore, regulatory approvals of targeted therapies like quizartinib have significantly expanded treatment options for patients. Notably, Nippon Shinyaku's recent launch of Vyxeos Combination for I.V. Injection in Japan marks a notable milestone, following the Ministry of Health, Labour and Welfare's approval for its use in treating high-risk AML.
Key Acute Myeloid Leukemia Treatment Company Insights
Notable players in the market include Astellas Pharma Inc.; Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY, LIMITED; and others, contributing to a vibrant competitive environment. The market is marked by pharmaceutical companies launching cutting-edge targeted therapies, immunotherapies, and personalized treatments, while diagnostics companies and healthcare institutions also vie for market share.
Bristol-Myers Squibb Company provides Onureg (azacitidine), an oral maintenance therapy approved for adult patients in complete remission. It enhances overall and relapse-free survival, serving as an important option for those ineligible for stem cell transplantation.
Jazz Pharmaceuticals plc offers Vyxeos (daunorubicin and cytarabine), a liposomal formulation approved for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. Vyxeos demonstrates improved overall survival compared to standard treatments, making it vital for high-risk AML patients.
Key Acute Myeloid Leukemia Treatment Companies:
The following are the leading companies in the acute myeloid leukemia treatment market. These companies collectively hold the largest market share and dictate industry trends.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- DAIICHI SANKYO COMPANY, LIMITED
- Jazz Pharmaceuticals plc
- Novartis AG
- Otsuka Pharmaceuticals Co.,Ltd.
- Pfizer Inc.
- Rigel Pharmaceuticals, Inc.
- Merck KGaA
- Sanofi
Recent Developments
In December 2024, the QuANTUM-Wild Phase 3 trial began in Japan and the U.S., assessing VANFLYTA’s efficacy combined with chemotherapy for patients with newly diagnosed FLT3-ITD negative acute myeloid leukemia.
In October 2024, MilliporeSigma announced a USD 76 million expansion of its ADC manufacturing capabilities in St. Louis, Missouri, tripling capacity to meet global demand and creating 170 new jobs.
In September 2024, Rigel expanded its partnership with Kissei, granting them exclusive rights to develop and commercialize REZLIDHIA in Japan, Korea, and Taiwan, receiving an upfront payment of USD 10 million.
In April 2024, Actinium revealed the results of the Phase 3 SIERRA trial for Iomab-B, showing a survival advantage in patients with high-risk relapsed or refractory acute myeloid leukemia who have TP53 mutations. These findings were accepted for oral presentation at the 50th European Bone Marrow Transplant Annual Meeting.
In December 2023, Venetoclax combined with Azacitidine and novel targeted therapies resulting from research advancements. The combination of venetoclax and Azacitidine emerged as a significant advancement in the treatment of acute myeloid leukemia (AML), particularly for older patients or those ineligible for intensive chemotherapy.
Acute Myeloid Leukemia Treatment Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 3.80 billion |
|
Revenue forecast in 2030 |
USD 6.29 billion |
|
Growth rate |
CAGR of 10.6% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2025 - 2030 |
|
Report updated |
March 2025 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
|
Segments covered |
Disease, treatment, route of administration, end use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, Australia, South Korea, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait |
|
Key companies profiled |
Quest Diagnostics Incorporated; Stryker; KARL STORZ SE & Co. KG; Olympus; Hamamatsu Photonics K.K.; Mizuho Medical Co.,Ltd.; Shimadzu Corporation; Leica Microsystems; Medtronic (Visionsense); PerkinElmer; Zeiss Group; FLUOPTICS SAS |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Acute Myeloid Leukemia Treatment Market Report Segmentation
We provide a comprehensive outlook of the global acute myeloid leukemia treatment market, forecasting revenue growth at various levels while dissecting industry trends across sub-segments from 2018 to 2030. This analysis is underpinned by The Research Insights's segmentation of the market into disease, treatment type, route of administration, end-use sector, and geographic region.
Disease Outlook (Revenue, USD Million, 2018 - 2030)
Myeloblastic Leukemia
Myelomonocytic Leukemia
Promyelocytic Leukemia
Monocytic Leukemia
Other Diseases
Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Chemotherapy
Anti-metabolites
Alkylating Agents
Anthracycline Drugs
Others
Targeted Therapy
FLT3 Inhibitors
Rydapt
Vanflyta
Xospata
IDH Inhibitors
Tibsovo
Rezlidhia
Idhifa
Mylotarg
BCL-2 Inhibitor
Hedgehog Pathway Inhibitor
Immunotherapy
Bispecific Antibodies
Antibody-drug Conjugates
Immune Checkpoint Inhibitors
Chimeric Antigen Receptor (CAR) T-cell Therapy
Other Treatments
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Parenteral
Oral
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals and Clinics
Specialty Centers
Homecare Setting
Ambulatory Care Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Comments
Post a Comment